ClinicalTrials.gg
RecruitingNCT06349486Updated Jan 15, 2026

Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication

An interventional study of vonoprazan, amoxicillin, tripotassium dicitrate bismuthate and vonoprazan, amoxicillin in Helicobacter Pylori Eradication, sponsored by Kaohsiung Medical University. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Kaohsiung Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Nov 2023, registered Apr 2024).
  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

  1. Compare the efficacies and safety of 14-day bismuth-amoxicillin-vonoprazan tiple therapy, 14-day vonoprazan dual therapy and 14-day rabeprazole triple therapy in the first-line treatment of H. pylori infection.
  2. To investigate the impacts of antibiotic resistance of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of anti-H. pylori treatments.
Read the detailed description

For this multi-center, randomized, open-label, superiority trial, we will recruit 780 adult patients with H. pylori infection from ten medical centers or regional hospitals in Taiwan. Using a computer generated randomized sequence, we randomly allocate patients (1:1:1; block size of six) to either 14-day bismuth-amoxicillin-vonoprazan triple therapy, 14-day vonoprazan dual therapy, or 14-day rabeprazole-triple therapy. Patients are asked to return at the second week to assess drug adherence and adverse events. Post-treatment H. pylori status is assessed by 13C-urea breath test at week 6. Participants with failure of H. pylori eradication will randomly receive either 14-day vonoprazan-based or 14-day esomeprazole-based bismuth quadruple therapy. Finally, the rates of eradication and adverse events will be compared between groups by chi-square test. Additionally, the effects of antibiotic resistances of H. pylori as well as CYP3A4, CYP2C19 and IL-1B -511 genotypes of host on the eradication efficacies of above first-line and second-line anti-H. pylori treatments are assessed by multivariate analysis.

02

Conditions studied

  • Helicobacter Pylori Eradication
03

In context

Lead sponsor

Kaohsiung Medical University is the lead sponsor of 56 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(1) At least 18 years old. (2) Subjects infected with Helicobacter pylori.

Exclusion criteria

Exclusion Criteria:

  1. Those who have ever received Helicobacter pylori sterilization treatment.
  2. Those who are allergic to the drugs used in this research.
  3. Those who have had stomach surgery.
  4. Those with severe liver cirrhosis or uremia or malignant tumors.
  5. Women who are pregnant or breastfeeding.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
390 participants (estimated)

Study arms

  • Active comparator
    bismuth-amoxicillin-vonoprazan triple therapy

    vonoprazan 20mg twice a day + amoxicillin 750mg four times a day + tripotassium dicitrate bismuthate 300mg four times a day

    Drug: vonoprazan, amoxicillin, tripotassium dicitrate bismuthate

  • Active comparator
    vonoprazan-amoxicillin dual therapy

    vonoprazan 20mg twice a day + amoxicillin 750mg,Four times a day

    Drug: vonoprazan, amoxicillin

  • Active comparator
    proton pump inhibitor-based standard triple therapy

    rabeprazole 20mg twice a day + amoxicillin 1gm twice a day + clarithromycin 500mg twice a day

    Drug: rabeprazole, amoxicillin, clarithromycin

Interventions

06

What researchers measure

Primary outcomes

  1. the eradication rate of Helicobacter pylori

    evalute eradication outcome by 13C urea breath test

    Time frame: 8 week after finishing study drugs

Secondary outcomes

  1. genotype analysis

    CYP3A4, CYP2C19 and IL-1B -511 genotypes

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2024
First posted
Apr 5, 2024
StartActual
Nov 28, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06349486
Lead sponsor
Kaohsiung Medical University
Responsible party
DENG-CHYANG WU (clinical professor, Kaohsiung Medical University) — Principal investigator
First posted
Apr 5, 2024
Start date
Nov 28, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 15, 2026

Study contacts

Deng-Chyang Wu, MD, PHD
Contact
dechwu@yahoo.com
88673121101 ext. 7451

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vonoprazan · Amoxicillin

Start the discussion